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Genetic polymorphisms in glycolytic pathway are
associated with the prognosis of patients with early stage
non-small cell lung cancer
J.E. Choi1, S.K. Do2, M.J. Hong1, J.H. Lee2, J.Y. Park3. 1 Cell
and Matrix Research Institute, Kyungpook National University
School of Medicine, Daegu, Republic of Korea, 2 Departments of
Biochemistry and Cell Biology, Kyungpook National University
School of Medicine, Daegu, Republic of Korea, 3 Department of
Internal Medicine, Kyungpook National University School of
Medicine, Daegu, Republic of Korea
Background: This study was conducted to investigate whether
polymorphisms of genes involved in glycolysis are associated with
the prognosis of patients with non-small cell lung cancer (NSCLC)
after surgical resection
Methods: Forty-four single nucleotide polymorphisms (SNPs) of
17 genes in glycolytic pathway were investigated in a total of 782
patients with NSCLC who underwent curative surgical resection.
The association of the SNPs with overall survival (OS) and disease
free survival (DFS) were analyzed.
Results: Among the 44 SNPs investigated, four SNPs (ENO1
rs227****A>G, PFKM rs1116****C>T, PFKP rs11*****C>T, PDK2
rs37*****G>A) were significantly associated with survival
outcomes in multivariate analyses. When stratified by tumor
histology, three SNPs (ENO1 rs227****A>G, PFKM rs11*****C>T,
and PDK2 rs37*****G>A) were significantly associated with OS
and/or DFS only in squamous cell carcinoma, whereas PFKP
rs11*****C>T exhibited a significant association with survival
outcomes only in adenocarcinoma. When the four SNPs were
combined, OS and DFS decreased as the number of bad genotypes
increased (Ptrend = 9×10–4 and 2×10–5, respectively). Promoter
assays showed that ENO1 rs227****G allele had significantly
higher promoter activity compared to the rs227****A allele
(P = 3×10–4).
Conclusions: The four SNPs, especially ENO1 rs227****A>G, may
be useful for the prediction of prognosis in patients with surgically
resected NSCLC. The effect of SNPs of glycolytic genes on survival
of NSCLC may differ depending on tumor histology. Further
studies are needed to confirm our findings and to understand
the role of glycolysis in determining prognosis in lung cancer.
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ALK activates ERK5, in both neuroblastoma and lung
cancer – a putative therapeutic target in cancer treatment
G. Umapathy. Medical Biochemistry and Cell Biology, The
Sahlgrenska Academy at Gothenburg University, Gothenburg,
Sweden
Background: ALK, a receptor tyrosine kinase, has been identified
as one partner in a wide variety of translocation events which
mediate an oncogenic response in different cancer types. A
number of small tyrosine kinase inhibitors (TKIs) have been
developed that act to inhibit ALK activity, the most studied of
these being crizotinib, a small competitive ATP-binding inhibitor
currently in clinical use in the treatment of ALK positive NSCLC
patients. Initial treatment of ALK+ neuroblastoma patients treated
with crizotinib has not provided as clear cut responses as those
observed in other cancer types, whereas with ALK+ NSCLC
patients it acquires resistance to crizotinib. The data accumulated
thus far suggests that monotherapy may not be the solution for all
ALK+ neuroblastoma and NSCLC patients, and that individualized
combinations of specific drugs might be a future solution to
address the disease.
Methods: Xenograft tumormodels, western blotting, proliferation
assay using resazurin, cell lines used ALK and EGFR positive
NSCLC cells.
Results: ERK5, a.k.a. BMK1, is suggested to play a vital role
in proliferation, differentiation, and survival. Previously, we
have shown that ERK5 activated by ALK through the pathway
PI3K/Akt/PKB/MEKK3, which contributes to cell growth of
neuroblastoma cell lines. Pharmacological inhibition or siRNA of
ERK5 results in decrease in growth of NSCLC cell lines, whereas
in combination with ALK inhibitor seems to be more effective
both in vitro and in vivo.
Conclusions: Taken together, our results indicate that ERK5
plays an important role in ALK and EGFR positive NSCLC cases,
suggesting that targeting ERK5 might be a potential therapeutic
target worthy of future exploration for NSCLC patients.
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University Faculty of Medicine Adana Uygulama Ve Arastirma
Mer., Adana, Turkey , 2 Thoracic Oncology, Baskent University
Faculty of Medicine Adana Uygulama Ve Arastirma Mer., Adana,
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Uygulama Ve Arastirma Mer., Adana, Turkey, 4Medical Oncology,
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Background: Lung cancer is the leading cause of cancer-related
mortality and responsible of 1.6 million deaths per year through
worldwide. Surgical resection with negative margin combined
with the adjuvant therapy [except for stage IA and IB (<4 cm)] is
the standard treatment for early stage Non-small cell lung cancer
(NSCLC). Early stage NSCLC, however, has relapse rate over 40%
mostly at distant sites. Therefore, high relapse rate necessitates
urgent novel biomarker for these patients. In this study, we aim
to evaluate the predictive and prognostic role of FOXP3+ Treg
cells along with well-defined clinicohistopathological factors in
early stage non-small cell lung cancer (NSCLC).
Methods: FOXP3 expression in tumor infiltrating lymphocytes
(TIL) was examined by immunohistochemical staining from
resected early stage 48 NSCLC patients. Data of patients
were analyzed retrospectively. FOXP3 expression status along
with common clinicohistopathological prognostic factors were
evaluated retrospectively.
Results: Median age of patients was 62 years-old (range 43–78).
Mean follow-up, median overall survival (OS), and disease
free survival (DFS) were 49, 49, and 30 months, respectively.
FOXP3 expression was positive in 23 (47.9%) patients. Adjuvant
chemotherapy (4 cycle of cisplatin-vinorelbine) were given to
16 patients (33.3%) at physician discretion. Increased rate of
FOXP3 expression are associated with worse OS and DFS with
p value of 0.016 and 0.032, respectively. In the patients with
high FOXP3 expression, platin based adjuvant chemotherapy had
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showed detrimental effect on DFS and OS with p value of 0.029
and 0.154 (40 vs 21 months), respectively.
Conclusions: These results suggest that FOXP3 expression in TIL
has a better prognostic potential in resected NSCLC. Our findings
also highlight the very high-risk group in resected NSCLC patients
with high FOXP3 staining intensity who did not get any benefit
even disfavor from adjuvant platin chemotherapy.
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Deltex-1 single nucleotide polymorphism rs1732786A>G
is associated with the prognosis of surgically resected
non-small cell lung cancer
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2 Radiology, Kyungpook National University School of Medicine,
Daegu, Republic of Korea, 3 Cell and Matrix Research Institute,
Kyungpook National University School of Medicine, Daegu,
Republic of Korea, 4 Biochemistry & Cell biology, Kyungpook
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Background: Notch signaling pathway has been implicated in the
prognosis of non-small cell lung cancer (NSCLC). This study was
conducted to determine the association between single nucleotide
polymorphisms (SNPs) in the Notch pathway genes and survival
outcomes of surgically resected NSCLC.
Methods: 252 SNPs in 28 candidate genes involved in Notch
pathway genes were extracted from the SABioscience, a Quiagen
company (http://www.sabiosiences.com). After quality control,
64 SNPs were analyzed in the discovery set (n = 354). A
replication study was performed (n = 772). All polymorphisms
were genotyped using SEQUENOM’s MassARRAY® iPLEX assay
according to instructions of the manufacturer. The genotype
association with overall survival (OS) and disease-free survival
(DFS) were analyzed.
Results: Among the 64 SNPs analyzed in the discovery set,
8 SNPs were significantly associated with OS or DFS. Among
the 9 SNPs, the association was consistently observed only for
DTX1 rs1732786A>G in the validation set. In combined analysis,
the rs1732786A>G was significantly associated with better OS
and DFS (adjusted HR [aHR] for OS, 0.81; 95% CI, 0.68–0.95;
P = 0.01; aHR for DFS, 0.82; 95% CI, 0.72–0.94; P = 0.003; under
codominant model). When categorized by pathological stage, the
rs1732786A>G was found to be significantly associated with
late stage (adjusted HR [aHR] for OS, 0.73; 95% CI, 0.60–0.89;
P = 0.002; under codominant model).
Conclusions: Our results suggest that the DTX1 rs1732786 A>G
could be a useful marker for predicting the prognosis of patients
with early stage NSCLC.
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Macrophage inhibitory cytokine-1 as a biomarker for diag-
nosis and prognosis of stage I–II non-small cell lung cancer
Y.-N. Liu, D. Shen, K.-L. Sun. Thoracic Surgery, Cancer Institute
and Hospital, Chinese Academy of Medical Sciences (CAMS),
Beijing, China
Background: Non-small cell lung cancer (NSCLC) is the leading
cause of cancer death and has a poor prognosis. Biomarkers
should be established to improve patient care especially in early-
stage NSCLC. The macrophage inhibitory cytokine-1 (MIC-1) can
promote tumor invasiveness and metastasis. Therefore, our aim
was to delineate the diagnostic and prognostic value of serum
MIC-1 in patients with early-stage NSCLC.
Methods: A total of 152 consecutive patients with stage I–II
NSCLC were retrospectively reviewed and underwent follow up
after total resection of tumor. Serum MIC-1 level was evaluated
in patients and 229 healthy controls, and was correlated with
clinical features and prognosis of patients.
Results: The level of MIC-1 of NSCLC patients was significantly
higher than that of controls (P < 0.001). A threshold of 1000 pg/ml
could be used to diagnose early-stage NSCLC with 96.5%
specificity and 71.3% sensitivity (area under curve, 0.912; 95%
CI, 0.886–0.939). Higher level of MIC-1 was associated with elder
age (>60 years old) at diagnosis (P = 0.001) and female gender
(P = 0.03). There was a significant difference between the overall
survival for patients with high level of MIC-1 (1000pg/ml) and
low level of MIC-1(log rank, P = 0.045). The overall 3-year survival
rate in patients with high level of MIC-1 was significantly lower
than that of patients with low MIC-1 level (84.0% vs. 97.8%,
P < 0.05). Cox regression revealed that a high level of MIC-1
was a potential risk factor (HR=7.848, 95%CI, 1.044–58.979)
for compromised overall survival.
Conclusions: The high level of serum MIC-1 might be served
as a potential biomarker for diagnosis and poorer outcome in
patients with early-stage NSCLC. The clinical significance could
be evaluated in future studies with larger sample size.
Legal entity responsible for the study: Cancer Institute and
Hospital, Chinese Academy of Medical Sciences.
Funding: Beijing Marathon of Hope special fund clinical topics
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Enumeration and molecular characterization of circulating
tumor cells in lung cancer patients using the GILUPI
CellCollector
C. Chudak1, J. Herrmann2, T. Lesser2. 1 Clinical Research, GILUPI
GmbH, Potsdam, Germany, 2 Clinic of Thoracic and Vascular
Surgery, SRH Waldklinikum Gera, Gera, Germany
Background: Analysis of tumor biopsy material represents
only assessable tumor and represents the state at the time of
diagnosis. This approach neglects tumoral heterogeneity changes
occurring during disease progression. However, during systemic
therapies tumors undergo molecular changes and usually develop
resistance mechanisms. Reevaluation of tumors after therapy,
at disease progression and before new treatment initiation
would be informative for the selection of appropriate next
steps. However, re-biopsies are not often feasible and can cause
morbidity. Liquid biopsy, i.e. isolating and analyzing circulating
tumor cells (CTCs), can be an additional source of diagnosis,
prognosis, evaluation of treatment efficacy, and molecular tumor
evolution and metastatic sites. The GILUPI CellCollector®, an
intravascularly in-dwelling device, screens blood for CTCs directly
in the vein of the cancer patient. The device has specific
